Next Generation Cancer Diagnostics Trends and Forecast
The future of the global next generation cancer diagnostics market looks promising with opportunities in the biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, and genetic analysis markets. The global next generation cancer diagnostics market is expected to reach an estimated $17.9 billion by 2030 with a CAGR of 11.0% from 2024 to 2030. The major drivers for this market are increasing prevalence of oncology disorders, requirement for effective prognosis and early detection of different types of cancer, as well as, growing efforts by important stakeholders to create novel approaches to address the growing need for effective diagnostics.Next Generation Cancer Diagnostics by Segment
The study includes a forecast for the global next generation cancer diagnostics by cancer type, technology, function, application, and region.Next Generation Cancer Diagnostics Market by Cancer Type [Shipment Analysis by Value from 2018 to 2030]
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Cervical Cancer
- Others
Next Generation Cancer Diagnostics Market by Technology [Shipment Analysis by Value from 2018 to 2030]
- Next-Generation Sequencing
- qPCR & Multiplexing
- Lab-On-A-Chip & Reverse Transcriptase-PCR
- Protein Microarrays
- DNA Microarrays
Next Generation Cancer Diagnostics Market by Function [Shipment Analysis by Value from 2018 to 2030]
- Therapeutic Monitoring
- Companion Diagnostics
- Prognostics
- Cancer Screening
- Risk Analysis
Next Generation Cancer Diagnostics Market by Application [Shipment Analysis by Value from 2018 to 2030]
- Biomarker Development
- CTC Analysis
- Proteomic Analysis
- Epigenetic Analysis
- Genetic Analysis
- Others
Next Generation Cancer Diagnostics Market by Region [Shipment Analysis by Value from 2018 to 2030]
- North America
- Europe
- Asia Pacific
- The Rest of the World
List of Next Generation Cancer Diagnostics Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies next generation cancer diagnostics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the next generation cancer diagnostics companies profiled in this report include-- Janssen Pharmaceuticals
- Illumina
- Novartis
- F. Hoffmann-La Roche
- Koninklijke Philips
- QIAGEN
- Agilent Technologies
- Abbott
- Thermo Fisher Scientific
- GE HealthCare
Next Generation Cancer Diagnostics Market Insights
The publisher forecasts that therapeutic monitoring will remain the largest segment over the forecast period due to the growing use of immunotherapies and targeted treatments in the treatment of cancer has increased the demand for efficient therapeutic monitoring.North America will remain the largest region over the forecast period due to the existence of a solid healthcare system and strong focus on cancer research.
Features of the Global Next Generation Cancer Diagnostics Market
- Market Size Estimates: Next generation cancer diagnostics market size estimation in terms of value ($B).
- Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
- Segmentation Analysis: Next generation cancer diagnostics market size by various segments, such as by cancer type, technology, function, application, and region in terms of value ($B).
- Regional Analysis: Next generation cancer diagnostics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
- Growth Opportunities: Analysis of growth opportunities in different cancer type, technology, function, application, and regions for the next generation cancer diagnostics market.
- Strategic Analysis: This includes M&A, new product development, and competitive landscape of the next generation cancer diagnostics market.
- Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the next generation cancer diagnostics market size?Answer: The global next generation cancer diagnostics market is expected to reach an estimated $17.9 billion by 2030.
Q2. What is the growth forecast for next generation cancer diagnostics market?
Answer: The global next generation cancer diagnostics market is expected to grow with a CAGR of 11.0% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the next generation cancer diagnostics market?
Answer: The major drivers for this market are increasing prevalence of oncology disorders, requirement for effective prognosis and early detection of different types of cancer, as well as, growing efforts by important stakeholders to create novel approaches to address the growing need for effective diagnostics.
Q4. What are the major segments for next generation cancer diagnostics market?
Answer: The future of the global next generation cancer diagnostics market looks promising with opportunities in the biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, and genetic analysis markets.
Q5. Who are the key next generation cancer diagnostics market companies?
Answer: Some of the key next generation cancer diagnostics companies are as follows:
- Janssen Pharmaceuticals
- Illumina
- Novartis
- F. Hoffmann-La Roche
- Koninklijke Philips
- QIAGEN
- Agilent Technologies
- Abbott
- Thermo Fisher Scientific
- GE HealthCare
Answer: The publisher forecasts that therapeutic monitoring will remain the largest segment over the forecast period due to the growing use of immunotherapies and targeted treatments in the treatment of cancer has increased the demand for efficient therapeutic monitoring.
Q7. In next generation cancer diagnostics market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to the existence of a solid healthcare system and strong focus on cancer research.
Q.8 Do we receive customization in this report?
Answer: Yes,the publisher provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the next generation cancer diagnostics market by cancer type (lung cancer, breast cancer, colorectal cancer, cervical cancer, and others), technology (next-generation sequencing, qPCR & multiplexing, lab-on-a-chip & reverse transcriptase-PCR , protein microarrays, and DNA microarrays), function (therapeutic monitoring, companion diagnostics, prognostics, cancer screening, and risk analysis), application (biomarker development, CTC analysis, proteomic analysis, epigenetic analysis, genetic analysis, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Global Next Generation Cancer Diagnostics Market: Market Dynamics
3. Market Trends and Forecast Analysis from 2018 to 2030
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
5. Competitor Analysis
6. Growth Opportunities and Strategic Analysis
7. Company Profiles of Leading Players
Companies Mentioned
- Janssen Pharmaceuticals
- Illumina
- Novartis
- F. Hoffmann-La Roche
- Koninklijke Philips
- QIAGEN
- Agilent Technologies
Methodology
The analyst has been in the business of market research and management consulting since 2000 and has published over 600 market intelligence reports in various markets/applications and served over 1,000 clients worldwide. Each study is a culmination of four months of full-time effort performed by the analyst team. The analysts used the following sources for the creation and completion of this valuable report:
- In-depth interviews of the major players in the market
- Detailed secondary research from competitors’ financial statements and published data
- Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
- A compilation of the experiences, judgments, and insights of professionals, who have analyzed and tracked the market over the years.
Extensive research and interviews are conducted in the supply chain of the market to estimate market share, market size, trends, drivers, challenges and forecasts.
Thus, the analyst compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. The analyst then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process.
LOADING...
